Federated Hermes Inc. Has $4.17 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Federated Hermes Inc. trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,100 shares of the medical instruments supplier’s stock after selling 1,010 shares during the quarter. Federated Hermes Inc.’s holdings in Becton, Dickinson and Company were worth $4,169,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Jeppson Wealth Management LLC raised its stake in Becton, Dickinson and Company by 4.0% in the 3rd quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock valued at $266,000 after acquiring an additional 40 shares during the period. CX Institutional lifted its stake in shares of Becton, Dickinson and Company by 3.0% during the 3rd quarter. CX Institutional now owns 1,491 shares of the medical instruments supplier’s stock worth $385,000 after buying an additional 43 shares during the last quarter. U.S. Capital Wealth Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.4% during the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock worth $339,000 after buying an additional 43 shares during the period. Value Partners Investments Inc. grew its stake in Becton, Dickinson and Company by 5.2% in the 3rd quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock valued at $225,000 after buying an additional 43 shares during the last quarter. Finally, Atlas Private Wealth Management raised its holdings in Becton, Dickinson and Company by 2.9% in the 3rd quarter. Atlas Private Wealth Management now owns 1,587 shares of the medical instruments supplier’s stock valued at $410,000 after acquiring an additional 45 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the topic of several research reports. Barclays upped their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. Raymond James upped their price objective on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $280.00.

Insider Activity

In other news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.5 %

NYSE BDX opened at $231.55 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The company has a market cap of $66.89 billion, a price-to-earnings ratio of 54.87, a PEG ratio of 1.93 and a beta of 0.43. The company has a 50 day moving average of $239.24 and a 200-day moving average of $241.42. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. During the same period in the prior year, the company posted $2.98 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.